Investors who bought Replimune Group securities between October 20, 2025, and April 10, 2026, can seek lead plaintiff status in a class action lawsuit alleging the company and executives made false statements about FDA approval prospects for its cancer drug RP1. The lawsuit claims Replimune misled investors by not addressing FDA concerns about study designs and submitting incomplete data, leading to the FDA rejecting the Biologics License Application in April 2026. Following the FDA rejection, Replimune's stock price dropped sharply. Investors have until October 5, 2026, to join the lawsuit and potentially recover losses.
US-listed XRP ETFs attracted $28.14 million on August 26, marking the second-largest daily inflow in 2026, led by Bitwise with $13.12 million. Whale wallets accumulated about 460 million XRP tokens, the strongest since February, signaling strong inst...
At Bitcoin Asia 2026 in Hong Kong, former Binance CEO Changpeng Zhao predicted Bitcoin will overtake gold's significance during the next bull market cycle. While gold's market cap is about $32.4 trillion, Bitcoin currently holds $1.6 trillion, with Z...
In 2026, the United States saw its share of Bitcoin's total mining hashrate decline by about 0.823%, losing roughly 55 exahash per second (EH/s), though it remains the largest miner globally. Meanwhile, China and Russia increased their share of the g...
Meta has agreed to an $18 billion legal settlement, which translates to about $1 billion per year—an amount negligible compared to its substantial revenue and earnings. The settlement resolves regulatory uncertainties, allowing Meta to focus on its c...
Genius Group, after selling its entire Bitcoin reserve to repay $8.5 million in debt, plans to rebuild its Bitcoin and AI treasuries to a combined $1.6 billion by fiscal year 2031. The company aims to grow total assets to $2 billion and will fund tre...
